Merck's (MRK) 'Plan to Win' Has Company Poised to Reclaim Position as Industry Leader, Chairman/CEO Makes Comments

April 24, 2007 3:22 PM EDT

Merck & Co's (NYSE: MRK) chairman, president, and chief executive officer, Richard T. Clark, makes comments on outlook for company.

Mr. Clark believes that the Company is on target to further reduce pipeline cycle-time, reaching a total 12-month reduction by the end of 2007. This cycle-time reduction helped to accelerate the development and launch of JANUVIA by as much as four years.

Merck's late-stage development pipeline includes three compounds that are in Phase III and another that is expected to move into Phase III later this year; two that the Company expects to file with the U.S. Food and Drug Administration (FDA) this year; and two that are currently under FDA review.

The four compounds currently in, or anticipated to enter Phase III in mid-2007, target four common disease areas with significant unmet medical needs: atherosclerosis, obesity, migraine and osteoporosis. In addition, Merck plans to file applications for ISENTRESS, which is on track to be the first drug in its class for the treatment of HIV infection, and MK-0524A, which combines Merck's extended-release niacin with MK-0524, a compound that reduces a common side effect of niacin therapy, flushing. Merck anticipates FDA action on both ARCOXIA and EMEND for Injection in the second quarter of 2007.

Related Categories

Guidance

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?